Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Joshua MillsteinUniversity of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0000-0001-7961-8943
Shahrad R RassekhDivision of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-8005-2641
Austin L BrownDepartment of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Cancer and Hematology Center, Houston, TX.ORCID 0000-0001-5802-5073
Qi NieUniversity of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0009-0005-1165-7782
Adam J EsbenshadeDivision of Pediatric Hematology and Oncology, Vanderbilt University Medical Center and the Vanderbilt Ingram Cancer Center, Nashville, TN.ORCID 0000-0002-0154-4996
Kristin R KnightDepartment of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, OR.
Michael E ScheurerDepartment of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Cancer and Hematology Center, Houston, TX.ORCID 0000-0002-8379-6088
Lillian SungDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0003-0951-3091
Diana J MokeDepartment of Pediatrics, Southern California Kaiser Permanente-Lynwood, Lynwood, CA.
Colin J D RossFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Michael WrightUniversity of Tennessee Health Science Center, Memphis, TN.
Victoria MenaDivision of Rehabilitation Services, Hearing and Speech, Children's Hospital Los Angeles, Los Angeles, CA.
Teresa RushingDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Pharmacy, Children's Hospital Los Angeles, Cancer and Blood Diseases Institute, Los Angeles, CA.ORCID 0000-0002-3655-7957
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-4485-4054
Etan OrgelCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.ORCID 0000-0002-1487-6818
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Statistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William JAMES GAUDERMAN · 2016 to 2026
$25.5M
Survivorship and Access to care for Latinos to Understand and Address health outcome Differences (SALUD)UH3CA260607 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Maria Monica Gramatges, LISA SCHUM KAHALLEY · 2023 to 2026
$6.3M
Survivorship and Access to care for Latinos to Understand and address Disparities (SALUD)UG3CA260607 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GRAMATGES, MARIA MONICA, KAHALLEY, LISA SCHUM · 2021 to 2022
$2.0M
Prevention of Cisplatin-induced Hearing Loss in Children with CancerK23DC014291 · NIDCD · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ORGEL, ETAN · 2016 to 2021
purposeCisplatin treats many common tumors but causes permanent and debilitating hearing loss (HL). The objective of this study was to develop and externally validate a predictive model of HL in cisplatin-treated children and adolescent cancer survivors.
methodsThe Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR) model architecture used several machine learning approaches followed by an ensemble predictor. The primary end point was post-treatment communication-affecting HL (International Society of Pediatric Oncology Ototoxicity Scale [SIOP] Grade ≥2). PedsHEAR was developed from a multicenter data set of cisplatin-exposed patients up to 21 years old (1984-2017) and externally validated using data from the Children's Oncology Group ACCL05C1 study (2007-2012) and two combined institutional cohorts (1988-2022). The model predicts post-treatment HL in each patient (probability [%], 95% CI) and classifies patients as low, intermediate, or high risk for HL (probability HL <0.33, 0.33-0.60, >0.60, respectively).
resultsIn the training data set (n = 1,115, median age 6.3 years, SIOP Grade ≥2 HL 44%), PedsHEAR demonstrated excellent discrimination (AUC, 0.93 [95% CI, 0.92 to 0.95]) and then successfully validated within the internal (testing; AUC, 0.79 [95% CI, 0.74 to 0.85]) and two external validation cohorts (AUC, 0.74 and AUC, 0.67). In an aggregate validation cohort (n = 631), the model predicted the probability of HL (AUC, 0.76 [95% CI, 0.72 to 0.79]) and classified 22% (141/631), 71% (447/631), and 7% (43/631) of patients as low, intermediate, or high risk for HL.
conclusionPedsHEAR predicted SIOP Grade ≥2 HL in pediatric cisplatin-treated patients. This is the first validated model to successfully predict cisplatin-induced HL in a broadly representative population treated with diverse regimens across a range of treatment settings.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy. · full record | OpenQuestion